Astrazeneca PLC ($AZN) Stock Forecast: Down 7.7% Today

What is Astrazeneca PLC?

Astrazeneca (AZN) Market: Astrazeneca (AZN) experienced a strong bearish movement today, closing at $64.90 with a -1.35% change from its previous close.

Why is Astrazeneca PLC going down?

AZN stock is down 7.7% on Apr 9, 2025 13:55

• The EU approval for expanded use of two separate cancer drugs by Astrazeneca did not seem to have a positive impact on the stock price, as it closed lower.
• Despite the positive news of Enhertu reducing the risk of disease progression in breast cancer patients and the expanded label for Imfinzi in lung cancer, investors may have been expecting even more significant developments.
• The market's reaction could indicate that investors were possibly concerned about other factors such as competition in the cancer drug market or overall market conditions, leading to the bearish movement in Astrazeneca's stock.

AZN Price Chart

AZN Technical Analysis

AZN News

Astrazeneca ( AZN ) Stock Moves -1.35%: What You Should Know

The latest trading day saw Astrazeneca (AZN) settling at $64.90, representing a -1.35% change from its previous close.

https://www.zacks.com/stock/news/2442275/astrazeneca-azn-stock-moves--135-what-you-should-know

AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs

The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.

https://www.zacks.com/stock/news/2441266/azn-gets-eu-nod-for-expanded-use-of-two-separate-cancer-drugs

European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings - AstraZeneca ( NASDAQ:AZN )

Enhertu reduced the risk of disease progression or death by 38% vs. chemotherapy in HR+, HER2-low metastatic breast cancer patients. AstraZeneca owes Daiichi Sankyo a $125 million milestone payment after the EU approval of Enhertu for certain breast cancer patients. With stocks plunging, steady ...

https://www.benzinga.com/general/biotech/25/04/44650506/european-drug-regulator-approves-astrazenecas-two-flagship-cancer-drugs-for-breast-and-lung-cance

Trending Today

Solana ($SOL) Crypto Forecast: Up 6.1% Today

Injective ($INJ) Crypto Forecast: Up 5.2% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 7.0% Today

Applovin Corporation ($APP) Stock Forecast: Down 6.4% Today

CRISPR Therapeutics AG ($CRSP) Stock Forecast: Up 6.3% Today

Movement ($MOVE) Crypto Forecast: Up 5.3% Today

The Trade Desk Inc ($TTD) Stock Forecast: Down 5.3% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 13.4% Today

Invesco Ltd ($IVZ) Stock Forecast: Down 6.3% Today

DexCom Inc. ($DXCM) Stock Forecast: Down 6.3% Today

Astrazeneca PLC Price History

30.09.2024 - AZN Stock was down 5.3%

• AstraZeneca's stock had a bearish movement despite the positive news of an exclusive worldwide license agreement with Monopar Therapeutics for ALXN-1840 to potentially treat Wilson disease.
• The market may have reacted negatively due to broader economic concerns impacting the pharmaceutical sector or profit-taking after a recent surge in the stock price.
• Investors might be cautious about the long-term implications of the agreement and its potential impact on AstraZeneca's financials.

09.03.2025 - AZN Stock was down 7.7%

• The EU approval for expanded use of two separate cancer drugs by Astrazeneca did not seem to have a positive impact on the stock price, as it closed lower.
• Despite the positive news of Enhertu reducing the risk of disease progression in breast cancer patients and the expanded label for Imfinzi in lung cancer, investors may have been expecting even more significant developments.
• The market's reaction could indicate that investors were possibly concerned about other factors such as competition in the cancer drug market or overall market conditions, leading to the bearish movement in Astrazeneca's stock.

05.10.2024 - AZN Stock was down 6.6%

• Despite the positive unveiling of early data from a weight loss drug partnership, AstraZeneca's stock experienced a bearish movement.
• The bullish stance taken by smart money in AZN options indicates a positive outlook, but the market movement suggests otherwise.
• It is possible that the market was expecting more substantial results or developments from the weight loss drug data, leading to disappointment and a bearish trend in the stock price.
• Investors may have been anticipating a stronger performance from AstraZeneca compared to the market, resulting in the stock trailing behind despite the positive data shared at the ObesityWeek 2024 event.

05.10.2024 - AZN Stock was down 6.6%

• Smart money investors have taken a bullish stance on AstraZeneca, as seen in the options market, but this did not translate into a positive movement in the stock price today.
• AstraZeneca unveiled early data from a Chinese-firm partnered oral weight loss drug, which could have generated mixed reactions from investors leading to the bearish movement.
• Despite a slight rise in the stock price, AstraZeneca still trailed the overall market, indicating that the news about the weight loss drug may not have been enough to offset other negative factors impacting the stock.

05.10.2024 - AZN Stock was down 7.1%

• The detention of current and former employees by Chinese authorities for alleged illegal activities in the pharmaceutical sector could have raised concerns among investors, leading to a bearish sentiment.
• Despite the positive unveiling of early data from a partnered oral weight loss drug, the overshadowing negative news regarding the investigation into potential data privacy law breaches might have impacted the stock negatively.
• The bullish stance taken by smart money in AZN options might not have been enough to counterbalance the negative sentiment stemming from the legal issues, resulting in the bearish movement.
• While the stock closed slightly higher in the most recent trading session, it still trailed the overall market performance, indicating that the concerns surrounding the investigation might be weighing down on investor confidence.

06.01.2025 - AZN Stock was up 5.9%

• AstraZeneca reported strong Q4 earnings with revenue exceeding expectations, particularly driven by higher sales in oncology and respiratory drugs.
• Despite facing potential fines in China, the company's positive financial outlook for FY25, projecting revenue growth and EPS growth, boosted investor confidence.
• The multiple class action lawsuits against AstraZeneca seem to have had minimal impact on the stock price, indicating that investors are more focused on the company's operational performance and future prospects.
• Overall, the bullish movement in AstraZeneca's stock today can be attributed to the robust Q4 earnings report and optimistic guidance for the future, outweighing any legal challenges the company currently faces.

16.03.2024 - AZN Stock was down 0.7%

• Promising data from the TOPAZ-1 Phase 3 trial of Imfinzi in combination with chemotherapy for biliary tract cancer was released, showing positive long-term overall survival results.
• Despite the positive news, the market may have reacted bearishly due to broader market conditions or profit-taking after recent gains.
• The volume spike in Aster DM Healthcare Ltd and other stocks could indicate shifting investor interest away from pharmaceuticals temporarily, impacting AZN's stock negatively.
• A warning shot fired by L%26G at AstraZeneca over executive pay could have also contributed to the bearish sentiment surrounding the stock.

04.03.2025 - AZN Stock was down 5.1%

• The partnership with OncoHelix to provide liquid biopsy testing for prostate cancer patients could be seen as a positive development, but the market may have already priced in this event.
• The FDA approval for Imfinzi's expanded use in bladder cancer indicates the company's commitment to advancing its oncology portfolio, which should have been a positive catalyst.
• Despite the positive developments, the market might have reacted bearishly due to concerns about competition in the oncology space or broader market conditions impacting pharmaceutical stocks.
• Investors may be uncertain about the potential market impact of the FDA approvals on AstraZeneca's revenue and profitability, leading to a cautious outlook and the bearish movement in the stock price.

04.03.2025 - AZN Stock was down 7.7%

• AstraZeneca received multiple approvals for its flagship cancer drugs and expanded indications for Imfinzi in bladder cancer, showcasing the company's commitment to developing cutting-edge treatments.
• Despite the positive developments on drug approvals and partnerships, the market reaction suggests that investors may have been expecting even more significant progress or revenue projections.
• The milestone payment owed to Daiichi Sankyo and the partnership with OncoHelix could indicate increased expenses or investments in research and development, potentially affecting short-term profitability and stock performance.
• There is uncertainty about the market's next move, which may have contributed to the bearish trend as investors exercise caution regarding the company's future growth prospects in the competitive pharmaceutical industry.